



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 13/08/2018

To, The Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Secretary Corporate Relationship Department, BSE Limited Dalal Street, P.J. Tower, Mumbai
--	---

Sub: - Submission of Un-Audited Financial Results for the Quarter ended on 30th June, 2018 along with Limited Review Report as per Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

Reference: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scripe Code: 524396;
NSE Symbol: BIOFILCHEM, ISIN No INE829A01014)

Dear Sir/Madam,

Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are enclosing Unaudited Financial results for the quarter ended on 30th June, 2018 together with a Limited Review Report of the Statutory Auditors.

Further, above result shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. These results shall also be uploaded on the website of the Company. i.e www.biofilgroup.net and on the website of the Stock Exchanges at www.bseindia.com and www.nseindia.com

This is for your information and record.


Thanking you,

Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN No. 00028819)



Statement of Standalone Unaudited Financial Results for the quarter ended 30th June 2018					
	Particulars	3 Month Ended 30/06/2018	3 Month Ended 30/06/2017	3 Month Ended 31/03/2018	Year ended March 31 2018
		Unaudited	Unaudited	Audited	Audited
I	Revenue from Operation	422.40	706.35	355.18	1236.00
II	Other Income	1.66	0.32	5.37	10.07
III	Total Revenue (I + II)	424.07	706.67	360.55	1246.07
IV	Expenses				
	(a) Cost of materials consumed	12.29	13.52	38.88	77.75
	(b) Purchases of stock-in-trade	413.14	663.75	278.08	991.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(59.39)	(2.20)	(85.80)	(91.70)
	(d) Employee benefits expense	21.19	5.69	31.89	72.93
	(e) Finance Cost	3.86	3.75	3.68	15.06
	(f) Depreciation and Amortisation Expense	7.49	7.11	8.30	29.63
	(g) Other expenses	19.08	5.28	66.03	92.53
	Total expenses (IV)	417.66	696.91	341.05	1187.25
V	Profit/ (Loss) before exceptional items and tax (III-IV)	6.41	9.76	19.49	58.82
VI	Exceptional Items	0.00		0.00	0.00
VII	Profit/ (Loss) before tax (V - VI)	6.41	9.76	19.49	58.82
VIII	Tax expense:				
	(1) Current tax	0.00		11.75	11.75
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00
IX	Profit/(Loss) for the period from continuing operation (VII-VIII)	6.41	9.76	7.74	47.07
X	Profit/(Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00
XII	Profit/(Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00
XIII	Profit/ (Loss) for the period (IX+XII)	6.41	9.76	7.74	47.07
XIV	Other Comprehensive Income	0.00	0.00	0.00	0.00
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss				
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss				
	c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	6.41	9.76	7.74	47.07
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38
XVIII	Earnings per equity shares (for continuing operation):				
	(1) Basic (Rs)	0.04	0.06	0.05	0.29
	(2) Diluted (Rs)	0.04	0.06	0.05	0.29





- 1 The above un-audited financial results of the company for the quarter and three month ended June 30, 2018 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on Aug 13, 2018.
- 2 The Limited Review of the financial Results of the Quarter ended 30th June 2018 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements Regulations 2015, has been carried out by the Statutory Auditors.
- 3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 - I. Pharma Product
 - II. Chemicals Division
 - III. Plastic Division
- 4 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 5 Effective 1st April 2018 the company adopted Ind AS 115 "Revenue from Contracts with Customers" using the cumulative retrospective transition method. The effect on adoption of Ind AS 115 was insignificant on the financial result
- 6 The revenue for the quarter ended 30th June 2018 is not comparable as it is reported net of Goods and Service Tax (GST)
- 7 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 8 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

Date : 13/08/2018

Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited


RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)



BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
CIN L24233MP1985PLC002709

Segmentwise Revenue, Results and Capital Employed for year ended 30 June-2018


(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30 , 2018	March 31, 2018	June 30 , 2017	31 March 2018
		Reviewed	Audited	Reviewed	Audited
1	Segment Revenue				
	Pharma Unit	381.43	301.03	679.30	1,053.13
	Chemicals Division	40.98	54.14	24.21	180.02
	Plastic Division	0.00	0.00	2.84	2.84
	Other	1.66	5.37	0.32	10.07
	Gross Turnover	424.07	360.55	706.67	1,246.07
2	Segment Results				
	Pharma Unit	4.62	30.78	15.71	56.31
	Chemicals Division	6.69	(6.55)	(1.29)	26.91
	Plastic Division	(1.07)	4.40	(0.91)	(4.01)
	Other	0.00	(8.41)	0.00	(8.41)
	Total Segment Profit Before Tax	10.24	20.22	13.51	70.79
	Interest Income	0.00	3.03	0.00	3.03
	Interest Expenses	3.83	3.75	3.75	15.00
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	6.41	19.49	9.76	58.82
	Provision for current tax	0.00	11.30	0.00	11.30
	Item Related Earlier Year	0.00	0.45	0.00	0.45
	Profit After Tax	6.41	7.75	9.76	47.07
3	Capital Employed				
	Segment Assets (A)				
	Pharma Division	1,262.13	1,485.86	1,896.85	1,485.86
	Chemicals Division	878.73	866.71	806.17	866.71
	Plastic Division	59.39	62.89	70.47	62.89
	Other				
	Total (A)	2,200.26	2,415.46	2,773.50	2,415.46
	Segment Liabilities (B)				
	Pharma Division	700.18	898.26	1299.62	898.26
	Chemicals Division	31.65	41.52	77.41	41.52
	Plastic Division	162.54	158.96	145.51	158.96
	Other				
	Total (B)	894.36	1,098.74	1,522.54	1,098.74
	Total Capital Employed (Segment Assets- Segment Liabilities)				
	Pharma Division	561.96	587.60	597.23	587.60
	Chemicals Division	847.08	825.19	728.76	825.19
	Plastic Division	(103.15)	(96.07)	(75.03)	(96.07)
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,305.89	1,316.73	1,250.96	1,316.73

DATE : 13/08/2018
PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819





Limited Review Report

The Board of Directors,
M/S Biofil Chemicals And Pharmaceuticals Limited
11/12, Sector E Sanwer Road
Industrial Area
Indore-452015 -M.P.

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter ended 30th June 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, SEBI Circular CIF/CFD/CMD/15/2015 dated 30th November 2015, and CIR/CFD/FAC/62/2016 dated 5th July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 13.08.2018

For Maheshwari & Gupta
Chartered Accountant
FRN: 006179C

CA Sunil Maheshwari
Partner

M No.403346

